Dr Sylwia Ammoun
Profiles

Dr Sylwia Ammoun

Senior Research Fellow

Peninsula Medical School (Faculty of Health)

Biography

Biography

Education and qualifications

  • 2005 PhD dissertation, Uppsala University, Sweden, Orexin Receptors in Recombinant CHO Cells. Signaling to Short- and Long Term Cells responses
  • 2004 Transfer, Uppsala University, Sweden
  • 1997 Degree of Master of Science, Uppsala University, Sweden Immunomodulatory-and-cytokine gene-cancer therapy
  • 1996 BScs, Uppsala University, Sweden

Professional membership

Member of South of England Brain Tumour Alliance (SEBTA)

Teaching

Teaching

Teaching interests

Teaching experience

I enjoy sharing my knowledge and always appreciate teaching in which I have over 20 years of experience.

Uppsala University, Sweden  

From 1998 to 2005 I taught medical-, pharmacology- and nurse-students in the following subjects: hemodynamics (blood-vascular circulation-system), the safety of medical equipment (current), optical refraction of the eye, heart anatomy (dissection), oscilloscope and pacemaker and muscle structure and function. During this time I also supervised undergraduate and BSc biomedical students and lab assistants.

Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK

From 2006 until present I have supervised PhD, MSc, BSc, and undergraduate students in different projects. Between 2006 and 2007 I taught medical students in 'Neurodegenerativedisorders' and 'Disease prevention and management-vaccines ‘and 2019 biomedical students in 'Tumours of the nervous system'.

Teaching education

  • 2014 Internal and External Doctoral Examiners training
  • 2011 Learning and Teaching for general Teaching Associates (GTA) training including: Theories of Learning and Teaching, Planning Sessions and Delivering Presentations, Learning in Groups, Evaluating Teaching and Giving Feedback, Assessment, Dealing with difficult Situations and Assessment Criteria and Marketing.
  • 2008 Problem-based learning (PBL) facilitator training.

Research

Research

Research interests

Research interests and experience

My previous career included the following projects: 1) The development of immunomodulatory cancer vaccines to treat Acute Myeloid Leukaemia (AML) (Clinical Immunology),2)Investigation of the role of endogenous retroviruses in Multiple Sclerosis(MS)(Clinical Virology) and 3) Revealing the signalling of orexinergic receptors towards cell fate determination (Neuroscience).

Since January 2006 I have been working at Professor Oliver Hanemann’s laboratory (Brain Tumour Centre Faculty of Health and Human Sciences - University of Plymouth ). My work has centered on the investigation of the mechanisms involved in the development of Neurofibromatosis type II-related and sporadic schwannoma and meningioma tumours of the nervous system, as well as defining potential therapeutics for this group of tumours.

Ph.D. students supervision: 6 PhD students as Director of Study (DoS), 4 PhD students as co-supervisor. 

Our research team have received an award from Neurofibromatosis (NF) Advocature in recognition of our research and continued commitment to NF2. Additionally, my work within theNF2 field contributed to two phase 0 clinical trials (as co-investigator) at our unit in collaboration with Manchester Hospital. 

Other research

Current projects

TAM family receptors as potential therapeutic targets in schwannoma and meningioma tumours (DoS)

The role of cellular prion Protein (PrPC) in the development of schwannoma and meningioma tumours (Dos)

The role of PrPC in the development of multi drug resistance (MDR) in schwannoma and meningioma tumours (DoS)


Previous projects

2013-2021

The role of Endogenous retroviruse type K (HERVK) in the development of schwannoma and meningioma tumours (DoS). Publication (2022) led to current clinical trials in Neurofibromatosis type II patients.

The project involved the investigation of the role of the endogenous retroviruses in tumourigenesis of schwannoma and meningioma tumours and testing anti HIV drugs as potential therapeutics.

The role of cellular Prion protein PrPC in the development of schwannoma tumours of the nervous system (DoS).

The project focused on the investigation of the overexpression and targetability of PrPC proteins in schwannoma tumours.

2011-2013

p53/mouse double minute 2homolog complex deregulation in Merlin-deficient tumours (First author)

This project involved the investigation of the role of p53 deregulation in schwannoma development and targeting pathways involved in p53 degradation. In this project, I was first author.

Gas6/Axl-family receptors in schwannoma pathological proliferation, adhesion and survival (First author)

In this project, we have investigated the role of Axl receptor inschwannoma pathological proliferation, cell-matrix adhesion, and survival. In this project, I was the first and corresponding author.

2010-2012

The role of insulin-like growth factors (IGF1/2) signalling inMerlin-deficient human schwannomas (First author)

and

Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival (First author)

In these studies, we have demonstrated that IGF1/2 and IGFBP-1 are released from schwannoma cells and IGF-I receptor overexpressed leading to increased schwannoma proliferation and cell-matrix adhesion. In these projects I was first author.

2010-2011

Nilotinib alone or incombination with selumetinib is a drug candidate for neurofibromatosis type 2 (First author)

In this project we have tested the therapeutic effectiveness of a PDGFRinhibitor Nilotinib and a MEK1/2 inhibitor selumetinib (AZD6244), in humanschwannoma in vitro model. In these projects I was firstauthor.

2009-2010

ErbB/HER receptoractivation and preclinical efficacy of lapatinib in vestibular schwannoma (First author)

This project was in collaboration with Dr Karajannis (USA) to test EGFR/HER inhibitor Lapatinib in human schwannoma in vitro model. In these projects I shared first authorship.

2008-2009

Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitorAZD6244 (First author)

In this study, we have tested the therapeutic effectiveness of a MEK1/2inhibitor AZD6244, in human schwannoma in vitro model. In these projects I was first author.

2007-2008

Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma (First author)

Here we demonstrated that PDGFRβ is strongly overexpressed in schwannoma cells leading to increased schwannoma proliferation. We have also successfully tested a PDGFR/Raf inhibitor Sorafenib. In these projects, I was the first author.

1999-2005

PhD project                                                                                          

Orexin Receptors in Recombinant CHO Cells. Signaling to Short- and Long Term Cells responses (First author and co-author)

The aim of this study was to investigate the mechanisms of orexin receptor coupling to the cascades regulating cell fate and also the assessment of the molecular determinants involved in orexin peptide-orexin receptor interaction.

1997-1998

Research project

Endogenous retroviruses in neurodegenerative diseases (co-author)

This project focused on the investigation of the expression of the endogenous retrovirus (ERV9)-related proteins in peripheral blood cells and presence in sera from multiple sclerosis (MS) patients.

1996-1997

MSc research project

Immunomodulatory-and-cytokine gene-cancer therapy

The aim of this was to design cancer vaccines to treat leukemia and lymphoma. The vaccines would be implemented in both immunotherapy and gene therapy. For immunotherapy, human blood monocytes were separated and differentiated into dendritic cells for antigen presentation and activation of cellular immunity. For cytokine gene therapy, genes for various cytokines were transferred into acute myeloid leukemia (AML) cells via retrovirus- and adenovirus-based vectors.

2011-2019

Clinical Research

I was involved in phase 0 clinical trials testing Sorafenib in Neurofibromatosis type 2 (NF2) patients. I perform tests on tumour tissue and blood samples from patients to look for the effect of these drugs on signalling pathways known to be involved in the development of Merlin-deficient tumours.

Research degrees awarded to supervised students

Supervisor of Ph.D. students: 6 students (DoS), 4 students (co-supervisor)

Grants & contracts

Research grants

2020 Animal Free Research UK:  Investigating the role of TYRO3, AXL and MERTK(TAM) receptors in Merlin deficient brain tumours; schwannomas and meningioma’: Â£84,369.79

2018  AnimalFree UK charity 01/08/2018-30/09/2018; ‘Investigating the role of TYRO3, AXL and MERTK(TAM) receptors in Merlin deficient brain tumours; schwannomas and meningioma’:£1,940.00.

2018 GreatOrmond Street Hospital Children'sCharity Grants: ‘Investigation and targeting cellular prion protein PrPC in neurofibromatosis type II related tumoursschwannomas, meningiomas and spinal ependymomas. Sylwia Ammoun: lead applicant and DoS; Oliver Hanemannco-applicant. £112,000, two years.

2016 ActionMedicalResearch for children: ‘The role of Endogenous Retroviral proteins in the development of Merlin-deficient tumours and as potential immunotherapy and/or drug targets’. Sylwia Ammoun: lead applicant and DoS, RobertBelshaw:co-applicant. September 2016-September 2018. Consumables£65,061.                                  

2015 InternalPhDstipend: ‘Endogenous Retroviral proteins as potential drug targets for Merlyn-deficient tumours and their role in tumour development.Sylwia Ammoun: lead applicant andDoS, Robert Belshaw: co-applicant. November 2016-November 2019. Student’s stipend, £61,000.

2014   Action on Hearing Loss Flexi grant, ‘Endogenous Retroviral proteins as potential immunotherapy and/or drug targets for Merlin-deficient tumours treatment and their role in vestibular neuroma development’. Sylwia Ammoun: lead applicant and DoS, Robert Belshaw: co-applicant. November 2014-April2014.Consumables £4697.

2014   TheLaura Crane Youth Cancer Trust grant, â€˜The role of prion proteinsinMerlin-deficient tumours’. Sylwia Ammon: principal applicant and DoS.October2014-October 2016. Consumables £24,000.

2013 InternalPhDstipend. ‘The role of cellular prion proteins in schwannoma and otherMerlin-deficient tumours’. Sylwia Ammoun: Principal applicant and DoS.October2013-October 2016. Student’s stipend £61,000.

2009 Northcott Devon Medical Foundation project grant, single applicant. The role of Insulinlike growth factors in schwannoma development.£5,000.

Publications

Publications

Key publications

Key publications are highlighted

Journals

Maze ï»¿EA, Agit B, Reeves S, Hilton DA, Parkinson DB, Laraba L, Ercolano E, Kurian KM, Hanemann CO, Belshaw RD, Ammoun S.
Corresponding authors: Belshaw RD and Ammoun S.
DoS: Sylwia Ammoun

Articles
Maze EA, Agit B, Reeves S, Hilton DA, Parkinson DB, Laraba L, Ercolano E, Kurian KM, Hanemann CO & Belshaw RD (2021) 'Human endogenous retrovirus type K promotes proliferation and confers sensitivity to anti-retroviral drugs in Merlin-negative schwannoma and meningioma' Cancer Research ,
Sofela AA, Hilton DA, Ammoun S, Baiz D, Adams CL, Ercolano E, Jenkinson MD, Kurian KM, Teo M & Whitfield PC (2021) 'Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas' International Journal of Molecular Sciences 22, (2) 560-560 ,
Hanemann CO, Ammoun S, Evans G, Hilton DA, Streeter A & Hayward C (2019) 'Phase 0 trial investigating the intra-tumoural concentration and activity of Sorafenib in Neurofibromatosis type 2' Journal of Neurology, Neurosurgery and Psychiatry ,
Stepanova DS, Semenova G, Kuo Y-M, Andrews AJ, Ammoun S, Hanemann CO & Chernoff J (2017) 'An essential role for the tumor suppressor Merlin in regulating fatty acid synthesis' Cancer Research ,
Provenzano L, Ryan Y, Hilton DA, Lyons-Rimmer J, Dave F, Maze EA, Adams CL, Rigby-Jones R, Ammoun S & Hanemann CO (2017) 'Cellular prion protein (PrPC) in the development of Merlin-deficient tumours' Oncogene ,
Zhou L, Lyons-Rimmer J, Ammoun S, Müller J, Lasonder E, Sharma V, Ercolano E, Hilton D, Taiwo I & Barczyk M (2015) 'The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors' Oncogene 35, (26) 3443-3453 ,
Ammoun S, Schmid MC, Zhou L, Hilton DA, Barczyk M & Hanemann CO (2015) 'The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours' Mol Oncol 9, (1) 236-248 ,
Provenzano L, Ammoun S & Hanemann CO (2014) 'THE ROLE OF CELLULAR PRION PROTEIN IN SCHWANNOMA AND OTHER MERLIN-DEFICIENT TUMOURS' ANTICANCER RESEARCH 34, (10) 6123-6123
Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, Hafizi S & Hanemann CO (2014) 'Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival' Oncogene 33, (3) 336-346 ,
Ammoun S, Provenzano L, Zhou L, Schmid MC & Hanemann CO (2014) 'IDENTIFICATION AND TARGETING PATHWAYS INVOLVED IN THE DEVELOPMENT OF MERLIN-DEFICIENT TUMOURS' ANTICANCER RESEARCH 34, (10) 5805-5805
Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW & Dombi E (2014) 'CTF Meeting 2012: Translation of the Basic Understanding of the Biology and Genetics of NF1, NF2, and Schwannomatosis Toward the Development of Effective Therapies' AMERICAN JOURNAL OF MEDICAL GENETICS PART A 164, (3) 563-578 ,
Shivane A, Parkinson DB, Ammoun S & Hanemann CO (2013) 'Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas' HISTOPATHOLOGY 62, (4) 651-656 ,
Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C & Hanemann CO (2012) 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas' Glia 60, (11) 1721-1733 ,
Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, Perks CM & Hanemann CO (2012) 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C, Hanemann CO. Glia. 2012 Nov;60(11):1721-33. doi: 10.1002/glia.22391. Epub 2012 Jul 20' Glia
Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, Perks CM & Hanemann CO (2012) 'Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival' Oncogene 31, (13) 1710-1722 ,
Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA & Hanemann CO (2011) 'Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways' Neoplasia 13, (12) 1101-1112 ,
Ammoun S, Schmid MC, Triner J, Manley P & Hanemann CO (2011) 'Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2' Neuro Oncol 13, (7) 759-766 ,
Ammoun S & Hanemann CO (2011) 'Emerging therapeutic targets in schwannomas and other merlin-deficient tumors' Nat Rev Neurol 7, (7) 392-399 ,
Ammoun S, Ristic N, Matthies C, Hilton DA & Hanemann CO (2010) 'Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244' Neurobiol Dis 37, (1) 141-146 ,
Flaiz C, Chernoff J, Ammoun S, Peterson JR & Hanemann CO (2009) 'PAK kinase regulates Rac GTPase and is a potential target in human schwannomas' Exp Neurol 218, (1) 137-144 ,
Ammoun S (2009) 'Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. Flaiz, Christine; Ammoun, Sylwia; Biebl, Anja; Hanemann, C. Oliver. Brain Pathology, Volume 19, Number 1, January 2009, pp. 27-38(12)'
Flaiz C, Ammoun S, Biebl A & Hanemann CO (2009) 'Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma' Brain Pathol 19, (1) 27-38 ,
Ammoun S, Flaiz C, Ristic N, Schuldt J & Hanemann CO (2008) 'Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma' Cancer Res 68, (13) 5236-5245 ,
Ammoun S (2006) 'OX1 orexin receptors activate extracellular signal-regulated kinase in Chinese hamster ovary cells via multiple mechanisms: the role of Ca2+ influx in OX1 receptor signaling. Ammoun S, Johansson L, Ekholm ME, Holmqvist T, Danis AS, Korhonen L, Sergeeva OA, Haas HL, Akerman KE, Kukkonen JP. Mol Endocrinol. 2006 Jan;20(1):80-99. Epub 2005 Sep 1'
Ammoun S (2006) 'G-protein-coupled OX1 orexin/hcrtr-1 hypocretin receptors induce caspase-dependent and -independent cell death through p38 mitogen-/stress-activated protein kinase. Ammoun S, Lindholm D, Wootz H, Akerman KE, Kukkonen JP. J Biol Chem. 2006 Jan 13;281(2):834-42. Epub 2005 Nov 10'
Ammoun S, Lindholm D, Wootz H, Ã…kerman KEO & Kukkonen JP (2005) 'G-protein-coupled OX1 Orexin/hcrtr-1 Hypocretin Receptors Induce Caspase-dependent and -independent Cell Death through p38 Mitogen-/Stress-activated Protein Kinase' Journal of Biological Chemistry 281, (2) 834-842 ,
Ammoun S, Johansson L, Ekholm ME, Holmqvist T, Danis AS, Korhonen L, Sergeeva OA, Haas HL, Ã…kerman KEO & Kukkonen JP (2005) 'OX<sub>1</sub>Orexin Receptors Activate Extracellular Signal-Regulated Kinase in Chinese Hamster Ovary Cells via Multiple Mechanisms: The Role of Ca<sup>2+</sup>Influx in OX<sub>1</sub>Receptor Signaling' Molecular Endocrinology 20, (1) 80-99 ,
Ammoun S (2005) 'OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms. Holmqvist T, Johansson L, Ostman M, Ammoun S, Akerman KE, Kukkonen JP. J Biol Chem. 2005 Feb 25;280(8):6570-9'
Holmqvist T, Johansson L, Östman M, Ammoun S, Åkerman KEO & Kukkonen JP (2004) 'OX1 Orexin Receptors Couple to Adenylyl Cyclase Regulation via Multiple Mechanisms' Journal of Biological Chemistry 280, (8) 6570-6579 ,
Kukkonen JP, Holmqvist T, Ammoun S & Ã…kerman KEO (2003) 'Erratum: Functions of the orexinergic/hypocretinergic system (American Journal of Physiology - Cell Physiology (December 2002) 283 (c1567-c1591))' American Journal of Physiology - Cell Physiology 284, (4 53-4)
Ammoun S (2003) 'Distinct recognition of OX1 and OX2 receptors by orexin peptides. Ammoun S, Holmqvist T, Shariatmadari R, Oonk HB, Detheux M, Parmentier M, Akerman KE, Kukkonen JP. J Pharmacol Exp Ther. 2003 May;305(2):507-14. Epub 2003 Jan 24'
Ammoun S, Holmqvist T, Shariatmadari R, Oonk HB, Detheux M, Parmentier M, Ã…kerman KEO & Kukkonen JP (2003) 'Distinct Recognition of OX<sub>1</sub> and OX<sub>2</sub>Receptors by Orexin Peptides' Journal of Pharmacology and Experimental Therapeutics 305, (2) 507-514 ,
Ammoun S (2002) 'Functions of the orexinergic/hypocretinergic system. Kukkonen JP, Holmqvist T, Ammoun S, Akerman KE. Am J Physiol Cell Physiol. 2002 Dec;283(6):C1567-91. Review. Erratum in: Am J Physiol Cell Physiol. 2003 Apr;284(4)'
Kukkonen JP, Holmqvist T, Ammoun S & Ã…kerman KEO (2002) 'Functions of the orexinergic/hypocretinergic system' American Journal of Physiology-Cell Physiology 283, (6) C1567-C1591 ,
Ammoun S (2001) 'Role of G-protein availability in differential signaling by alpha 2-adrenoceptors. Nasman J, Kukkonen JP, Ammoun S, Akerman KE. Biochem Pharmacol. 2001 Oct 1;62(7):913-22'
Nasman J, Kukkonen JP, Ammoun S & Akerman KEO (2001) 'Role of G-protein availability in differential signaling by alpha 2-adrenoceptors 1 1Abbreviations: α2-AR, α2-adrenergic receptor; AC, adenylyl cyclase; GTPγS, guanosine 5′-O-(3-thiotriphosphate); IBMX, 3-isobutyl-1-methyl-xanthine; UK14,304, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine' Biochemical Pharmacology 62, (7) 913-922 ,
Ammoun S (2000) 'Recombinant expression of a selective blocker of M(1) muscarinic receptors. Näsman J, Jolkkonen M, Ammoun S, Karlsson E, Akerman KE. Biochem Biophys Res Commun. 2000 May 10;271(2):435-9'
Näsman J, Jolkkonen M, Ammoun S, Karlsson E & Åkerman KEO (2000) 'Recombinant Expression of a Selective Blocker of M1 Muscarinic Receptors' Biochemical and Biophysical Research Communications 271, (2) 435-439 ,
Ammoun S (1999) 'Retroviral RNA related to ERV9/MSRV in a human serum: a new sequence variant. Olsson P, Ryberg B, Awad R, Ammoun S, Yin H, Hjalmarsson S, Blomberg J. AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):591-3'
Olsson P, Ryberg B, Awad R, Ammoun S, Yin H, Hjalmarsson S & Blomberg J (1999) 'Retroviral RNA Related to ERV9/MSRV in a Human Serum: A New Sequence Variant' AIDS Research and Human Retroviruses 15, (6) 591-593 ,
Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO & Karajannis MA 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro-oncology ,
Chapters
Oliver Hanemann C & Ammoun S (2010) 'Receptor Tyrosine Kinases in Human Schwannoma' Angiogenesis &amp;amp Therapeutic Targets In Cancer BENTHAM SCIENCE PUBLISHERS 90-98 ,
Conference Papers
Hanemann CO, Zhou L, Ammoun S, Lasonder E, Sharma V, Muller J & Ercolano E (2015) 'Abstract 704: Scaffold protein KSR1 is negatively regulated by merlin and promotes tumor development in merlin deficient tumors' American Association for Cancer Research (AACR) 704-704 ,
Hanemann CO, Ammoun S, Schmid MC & Zhou L (2014) 'Abstract 2609: The role of focal adhesion kinase (FAK), PI3K/AKT and p53/mouse double minute 2 homologue (MDM2) complex in the pathobiology of Merlin-deficient tumors' American Association for Cancer Research (AACR) 2609-2609 ,
Hilton D, Shivane A, Kirk L, Ammoun S & Hanemann CO (2014) 'Growth factor signaling pathway activation in meningiomas' 101-101
Hilton DA, Shivane A, Turner L, Ammoun S & Hanemann O (2013) 'Activation of multiple signalling pathways in meningiomas is unrelated to NF2 gene status' 35-35
Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk M & Hanemann CO (2012) 'MERLIN DEFICIENT HUMAN TUMOURS SHOW LOSS OF CONTACT INHIBITION, ACTIVATION OF WNT/β-CATENIN SIGNALING LINKED TO THE PDGFR/SRC AND RAC/PAK PATHWAYS' 5-6
Ammoun S, Zhou L, Barczyk M, Hilton D, Hafizi S & Hanemann CO (2011) 'GAS6/AXL-FAMILY RECEPTORS IN SCHWANNOMA PATHOLOGICAL PROLIFERATION, ADHESION AND SURVIVAL' 1-1
Schmid MC, Zhou L, Ammoun S & Hanemann CO (2010) 'Targeting focal adhesion kinase (FAK) in primary human schwannoma' 42-42 ,
Hanemann CO, Ammoun S, Schmid MC, Ristic N, Ercolano E & Zhou L (2010) 'IGF/IGFBP SIGNALING IN MERLIN-DEFICIENT TUMORS' 22-22
Ammoun S, Schmid MC & Hanemann CO (2009) 'Abstract C164: Targeting receptor tyrosine kinases and their downstream signaling pathways in human schwannoma' American Association for Cancer Research (AACR) C164-C164 ,
Hanemann CO & Ammoun S (2009) 'MERLIN'S TUMOURS: FROM BENCH TO BEDSIDE' ,
Mackay L, Higgins S, Abderrahim A, Mistry P, Ammoun S, Whitaker G, Akinwunmi J, Hanneman CO & Pilkington GJ (2008) 'IGF-BP1/2 expression in histological sections, biopsy-derived cell cultures and cyst fluids from nervous system neoplasms' 21-21
Presentations and posters
Ammoun S & Hanemann O Ammoun S & Hanemann O 'Strong and long-lasting activation of ERK in human schwannoma cells'
Ammoun S, Maze EA, Agit B, Belshaw R & Hanemann CO Ammoun S, Maze EA, Agit B, Belshaw R & Hanemann CO 'Abstract 1164: Human endogenous retrovirus type K promotes proliferation of Merlin negative schwannoma and meningioma which can be inhibited by anti-retroviral and anti-TEAD drugs' ,
Maze E, Reeves S, Hilton D, Provenzano L, Belshaw R & Ammoun S Maze E, Reeves S, Hilton D, Provenzano L, Belshaw R & Ammoun S 'Abstract 4627: The role of human endogenous retroviral proteins in the development of Merlin-deficient tumors and as potential drug targets' ,
Dave F, Ammoun S & Hanemann CO Dave F, Ammoun S & Hanemann CO 'Abstract 941: TAM receptors as potential therapeutic targets in NF2-related schwannomas and meningiomas' ,
Hanemann CO, Maze E, Agit B, Reeves S, Hilton D, Parkinson DB, Laraba L, Ercolano E, Kurian K & Belshaw R Hanemann CO, Maze E, Agit B, Reeves S, Hilton D, Parkinson DB, Laraba L, Ercolano E, Kurian K & Belshaw R 'Human Endogenous Retrovirus Type K promotes proliferation of Merlin-negative schwannoma and meningioma which can be inhibited by anti-retroviral and anti-TEAD drugs' ,
Ammoun S, Dave F, Hilton D, Adams C, Elcorano E, Hafizi S & Hanemann CO Ammoun S, Dave F, Hilton D, Adams C, Elcorano E, Hafizi S & Hanemann CO 'INVESTIGATING THE ROLE OF TAM FAMILY RECEPTORS IN MERLIN DEFICIENT TUMOURS' ,
Ammoun DS, Maze ME, Reeves MS, Hilton DD, Ercolano DE, Hamemann PO & Belshaw DR Ammoun DS, Maze ME, Reeves MS, Hilton DD, Ercolano DE, Hamemann PO & Belshaw DR 'PP03. HUMAN ENDOGENOUS RETROVIRUS TYPE K (HERVK) PROTEINS ARE OVEREXPRESSED AND RELEASED FROM HUMAN PRIMARY SCHWANNOMA CELLS CONTRIBUTING TO TUMOUR DEVELOPMENT VIA ERK, AKT, FAK PATHWAYS ACTIVATION AND P53 DOWNREGULATION' ,
Dave F, Ammoun S & Hanemann CO Dave F, Ammoun S & Hanemann CO 'TAM receptors as potential therapeutic targets in NF2-related schwannomas and meningiomas'
Shivane A, Ammoun S, Parkinson DB & Hanemann CO Shivane A, Ammoun S, Parkinson DB & Hanemann CO 'EXPRESSION OF C-JUN & SOX-2 IN HUMAN SCHWANNOMAS AND TRAUMATIC NEUROMAS' ,